Zhou, J., Zhang, X., Guo, C., Wang, H., Sun, Y., Liang, X., Chu, Q., Wu, L., Zhou, C., Fang, J., Pan, Y., Cui, J., Huang, Z., Chen, Y., Zhou, C., Liu, X., Yang, Y., Li, N., Zhang, T., Zhou, H. (2026). First-in-class PD-1/IL-2
                    <sup>α-bias</sup>
                    bispecific antibody IBI363 (TAK-928) in patients (pts) with advanced immunotherapy-resistant non–small cell lung cancer (NSCLC): Updated results from a phase I study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2618